A plasma long-chain acylcarnitine predicts cardiovascular mortality in incident dialysis patients.

J Am Heart Assoc
Authors
Keywords
Abstract

BACKGROUND: The marked excess in cardiovascular mortality that results from uremia remains poorly understood.

METHODS AND RESULTS: In 2 independent, nested case-control studies, we applied liquid chromatography-mass spectrometry-based metabolite profiling to plasma obtained from participants of a large cohort of incident hemodialysis patients. First, 100 individuals who died of a cardiovascular cause within 1 year of initiating hemodialysis (cases) were randomly selected along with 100 individuals who survived for at least 1 year (controls), matched for age, sex, and race. Four highly intercorrelated long-chain acylcarnitines achieved the significance threshold adjusted for multiple testing (P

CONCLUSIONS: Our data highlight clinically meaningful alterations in acylcarnitine homeostasis at the time of dialysis initiation, which may represent an early marker, effector, or both of uremic cardiovascular risk.

Year of Publication
2013
Journal
J Am Heart Assoc
Volume
2
Issue
6
Pages
e000542
Date Published
2013 Dec 05
ISSN
2047-9980
URL
DOI
10.1161/JAHA.113.000542
PubMed ID
24308938
PubMed Central ID
PMC3886735
Links
Grant list
K08 DK090142 / DK / NIDDK NIH HHS / United States
K24 DK094872 / DK / NIDDK NIH HHS / United States
K08-DK-090142 / DK / NIDDK NIH HHS / United States
R21-DK-071674 / DK / NIDDK NIH HHS / United States